Latest Articles
Merck endometrial cancer drug meets survival goals in phase 3 trial - StreetInsider
Merck endometrial cancer drug meets survival goals in phase 3 trial StreetInsider
Published: May 18, 2026, 10:47 a.m.
CT and international research team advances understanding of disease that impacts women worldwide - Hartford Courant
CT and international research team advances understanding of disease that impacts women worldwide Hartford Courant
Published: May 18, 2026, 9:46 a.m.
"The disease took everything from me": This athlete opens up about her battle against endometriosis - MSN
"The disease took everything from me": This athlete opens up about her battle against endometriosis MSN
Published: May 17, 2026, 10:18 p.m.
"The disease took everything from me": this athlete opens up about her battle against endometriosis - The Body Optimist
"The disease took everything from me": this athlete opens up about her battle against endometriosis The Body Optimist
Published: May 17, 2026, 1:25 p.m.
Alex Marquardt’s CNN Exit Follows Fallout From Defamation Case - MSN
Alex Marquardt’s CNN Exit Follows Fallout From Defamation Case MSN
Published: May 16, 2026, 7:23 p.m.
Teddi Mellencamp bravely showcases brain surgery scars as she battles stage 4 cancer: 'Sick of the wigs' - MSN
Teddi Mellencamp bravely showcases brain surgery scars as she battles stage 4 cancer: 'Sick of the wigs' MSN
Published: May 14, 2026, 5:46 p.m.
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer - Minichart
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer Minichart
Published: May 14, 2026, 4:30 p.m.
Phase 3 endometrial cancer trial enrollment wraps as Q1 revenue hits $35.1M - Stock Titan
Phase 3 endometrial cancer trial enrollment wraps as Q1 revenue hits $35.1M Stock Titan
Published: May 14, 2026, 11:30 a.m.
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - PR Newswire
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PR Newswire
Published: May 14, 2026, 11:30 a.m.
Press Release: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - Moomoo
Press Release: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment Moomoo
Published: May 14, 2026, 11:30 a.m.
Link copied to clipboard!